Acorda Therapeutics

Acorda Therapeutics develops therapies to improve neurological function in people with Parkinson’s disease, multiple sclerosis and other neurological disorders. It manufactures and markets Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the US. Its ARCUS technology transforms medicines into light, respirable dry powders.
Acorda Therapeutics is a biotechnology company that develops therapies to improve neurological function in people with Parkinson’s disease, multiple sclerosis and other neurological disorders. The company manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the US. Its ARCUS technology platform transforms medicines into light, respirable dry powders.